Literature DB >> 25846299

The aqueous phase of Alzheimer's disease brain contains assemblies built from ∼4 and ∼7 kDa Aβ species.

Jessica M Mc Donald1, Tiernan T O'Malley2, Wen Liu1, Alexandra J Mably1, Gunnar Brinkmalm3, Erik Portelius3, William M Wittbold4, Matthew P Frosch5, Dominic M Walsh6.   

Abstract

INTRODUCTION: Much knowledge about amyloid β (Aβ) aggregation and toxicity has been acquired using synthetic peptides and mouse models, whereas less is known about soluble Aβ in human brain.
METHODS: We analyzed aqueous extracts from multiple AD brains using an array of techniques.
RESULTS: Brains can contain at least four different Aβ assembly forms including: (i) monomers, (ii) a ∼7 kDa Aβ species, and larger species (iii) from ∼30-150 kDa, and (iv) >160 kDa. High molecular weight species are by far the most prevalent and appear to be built from ∼7 kDa Aβ species. The ∼7 kDa Aβ species resist denaturation by chaotropic agents and have a higher Aβ42/Aβ40 ratio than monomers, and are unreactive with antibodies to Asp1 of Ab or APP residues N-terminal of Asp1. DISCUSSION: Further analysis of brain-derived ∼7 kDa Aβ species, the mechanism by which they assemble and the structures they form should reveal therapeutic and diagnostic opportunities.
Copyright © 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Amyloid β-protein; Oligomers; SDS-Stable dimer

Mesh:

Substances:

Year:  2015        PMID: 25846299      PMCID: PMC4592782          DOI: 10.1016/j.jalz.2015.01.005

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  66 in total

1.  Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease.

Authors:  C A McLean; R A Cherny; F W Fraser; S J Fuller; M J Smith; K Beyreuther; A I Bush; C L Masters
Journal:  Ann Neurol       Date:  1999-12       Impact factor: 10.422

Review 2.  The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes.

Authors:  Iryna Benilova; Eric Karran; Bart De Strooper
Journal:  Nat Neurosci       Date:  2012-01-29       Impact factor: 24.884

3.  Solution state characterization of amyloid beta-derived diffusible ligands.

Authors:  Robert W Hepler; Karen M Grimm; Deborah D Nahas; Robert Breese; Elizabeth Chen Dodson; Paul Acton; Paul M Keller; Mark Yeager; Hui Wang; Paul Shughrue; Gene Kinney; Joseph G Joyce
Journal:  Biochemistry       Date:  2006-12-06       Impact factor: 3.162

4.  Mouse monoclonal antibodies to human immunodeficiency virus glycoprotein 120 generated by repeated immunization with glycoprotein 120 from a single isolate, or by sequential immunization with glycoprotein 120 from three isolates.

Authors:  J P Reeves; C Y Lo; D M Klinman; S L Epstein
Journal:  Hybridoma       Date:  1995-06

5.  Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease.

Authors:  K Johnson-Wood; M Lee; R Motter; K Hu; G Gordon; R Barbour; K Khan; M Gordon; H Tan; D Games; I Lieberburg; D Schenk; P Seubert; L McConlogue
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

6.  Neurotoxic protein oligomers--what you see is not always what you get.

Authors:  Gal Bitan; Erica A Fradinger; Sean M Spring; David B Teplow
Journal:  Amyloid       Date:  2005-06       Impact factor: 7.141

7.  Properties of an asymmetrical flow field-flow fractionation channel having one permeable wall.

Authors:  K G Wahlund; J C Giddings
Journal:  Anal Chem       Date:  1987-05-01       Impact factor: 6.986

Review 8.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

9.  Appearance of sodium dodecyl sulfate-stable amyloid beta-protein (Abeta) dimer in the cortex during aging.

Authors:  M Enya; M Morishima-Kawashima; M Yoshimura; Y Shinkai; K Kusui; K Khan; D Games; D Schenk; S Sugihara; H Yamaguchi; Y Ihara
Journal:  Am J Pathol       Date:  1999-01       Impact factor: 4.307

10.  Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosis.

Authors:  Jungsu Kim; Adam E M Eltorai; Hong Jiang; Fan Liao; Philip B Verghese; Jaekwang Kim; Floy R Stewart; Jacob M Basak; David M Holtzman
Journal:  J Exp Med       Date:  2012-11-05       Impact factor: 14.307

View more
  23 in total

1.  Liquid and Hydrogel Phases of PrPC Linked to Conformation Shifts and Triggered by Alzheimer's Amyloid-β Oligomers.

Authors:  Mikhail A Kostylev; Marcus D Tuttle; Suho Lee; Lauren E Klein; Hideyuki Takahashi; Timothy O Cox; Erik C Gunther; Kurt W Zilm; Stephen M Strittmatter
Journal:  Mol Cell       Date:  2018-10-25       Impact factor: 17.970

2.  PrP-grafted antibodies bind certain amyloid β-protein aggregates, but do not prevent toxicity.

Authors:  David Mengel; Wei Hong; Grant T Corbett; Wen Liu; Alexandra DeSousa; Laura Solforosi; Cheng Fang; Matthew P Frosch; John Collinge; David A Harris; Dominic M Walsh
Journal:  Brain Res       Date:  2018-12-26       Impact factor: 3.252

3.  Protein folding, misfolding and aggregation: The importance of two-electron stabilizing interactions.

Authors:  Andrzej Stanisław Cieplak
Journal:  PLoS One       Date:  2017-09-18       Impact factor: 3.240

4.  Identification of neurotoxic cross-linked amyloid-β dimers in the Alzheimer's brain.

Authors:  Gunnar Brinkmalm; Wei Hong; Zemin Wang; Wen Liu; Tiernan T O'Malley; Xin Sun; Matthew P Frosch; Dennis J Selkoe; Erik Portelius; Henrik Zetterberg; Kaj Blennow; Dominic M Walsh
Journal:  Brain       Date:  2019-05-01       Impact factor: 13.501

5.  A vicious cycle of β amyloid-dependent neuronal hyperactivation.

Authors:  Benedikt Zott; Manuel M Simon; Wei Hong; Felix Unger; Hsing-Jung Chen-Engerer; Matthew P Frosch; Bert Sakmann; Dominic M Walsh; Arthur Konnerth
Journal:  Science       Date:  2019-08-09       Impact factor: 47.728

6.  The Aggregation Paths and Products of Aβ42 Dimers Are Distinct from Those of the Aβ42 Monomer.

Authors:  Tiernan T O'Malley; William M Witbold; Sara Linse; Dominic M Walsh
Journal:  Biochemistry       Date:  2016-10-26       Impact factor: 3.162

7.  Anti-Aβ antibodies incapable of reducing cerebral Aβ oligomers fail to attenuate spatial reference memory deficits in J20 mice.

Authors:  Alexandra J Mably; Wen Liu; Jessica M Mc Donald; Jean-Cosme Dodart; Frédérique Bard; Cynthia A Lemere; Brian O'Nuallain; Dominic M Walsh
Journal:  Neurobiol Dis       Date:  2015-07-26       Impact factor: 5.996

8.  Human Brain-Derived Aβ Oligomers Bind to Synapses and Disrupt Synaptic Activity in a Manner That Requires APP.

Authors:  Zemin Wang; Rosemary J Jackson; Wei Hong; Walter M Taylor; Grant T Corbett; Arturo Moreno; Wen Liu; Shaomin Li; Matthew P Frosch; Inna Slutsky; Tracy L Young-Pearse; Tara L Spires-Jones; Dominic M Walsh
Journal:  J Neurosci       Date:  2017-11-03       Impact factor: 6.167

9.  A human scFv antibody that targets and neutralizes high molecular weight pathogenic amyloid-β oligomers.

Authors:  Adriano Sebollela; Erika N Cline; Izolda Popova; Kevin Luo; Xiaoxia Sun; Jay Ahn; Milena A Barcelos; Vanessa N Bezerra; Natalia M Lyra E Silva; Jason Patel; Nathalia R Pinheiro; Lei A Qin; Josette M Kamel; Anthea Weng; Nadia DiNunno; Adrian M Bebenek; Pauline T Velasco; Kirsten L Viola; Pascale N Lacor; Sergio T Ferreira; William L Klein
Journal:  J Neurochem       Date:  2017-08-02       Impact factor: 5.372

10.  N-Terminal Extensions Retard Aβ42 Fibril Formation but Allow Cross-Seeding and Coaggregation with Aβ42.

Authors:  Olga Szczepankiewicz; Björn Linse; Georg Meisl; Eva Thulin; Birgitta Frohm; Carlo Sala Frigerio; Michael T Colvin; Angela C Jacavone; Robert G Griffin; Tuomas Knowles; Dominic M Walsh; Sara Linse
Journal:  J Am Chem Soc       Date:  2015-11-17       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.